NASDAQ:PODD - Insulet Stock Price, Forecast & News

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $192.12 million during the quarter, compared to analysts' expectations of $179.50 million. The company's revenue for the quarter was up 27.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.03 earnings per share. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

Insulet will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

17 analysts have issued 12-month price targets for Insulet's shares. Their forecasts range from $100.00 to $213.00. On average, they anticipate Insulet's stock price to reach $162.06 in the next year. This suggests that the stock has a possible downside of 23.7%. View Analyst Price Targets for Insulet.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

News articles about PODD stock have been trending somewhat positive on Monday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insulet earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), Hologic (HOLX), Masimo (MASI), ABIOMED (ABMD), Hill-Rom (HRC), Globus Medical (GMED) and Integra Lifesciences (IART).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), DexCom (DXCM), Splunk (SPLK), Tandem Diabetes Care (TNDM), Adobe (ADBE), Roku (ROKU), salesforce.com (CRM) and Veeva Systems (VEEV).

Insulet's stock is owned by many different of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (2.59%), Fred Alger Management LLC (2.34%), Eagle Asset Management Inc. (0.99%), Lord Abbett & CO. LLC (0.88%), Renaissance Technologies LLC (0.81%) and Bank of New York Mellon Corp (0.80%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Fred Alger Management LLC, Goldman Sachs Group Inc., Jennison Associates LLC, Eagle Asset Management Inc., Russell Investments Group Ltd., Marshall Wace North America L.P. and First Trust Advisors LP. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

PODD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Beacon Investment Advisory Services Inc., Sumitomo Mitsui Trust Holdings Inc., UBS Asset Management Americas Inc., Swiss National Bank, SG Americas Securities LLC, Cubist Systematic Strategies LLC and Trexquant Investment LP. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $212.32.